Stephan Kruger1, Michael Haas1, Philipp Johannes Burger1, Steffen Ormanns2, Dominik Paul Modest1, Christoph Benedikt Westphalen1, Axel Kleespies3, Martin Kurt Angele3, Werner Hartwig3, Christiane Josephine Bruns4, Thomas Kirchner2, Jens Werner3, Volker Heinemann1, Stefan Boeck5. 1. Department of Internal Medicine III, Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany. 2. Institute of Pathology, Ludwig-Maximilians-University of Munich, 81377, Munich, Germany. 3. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, 81377, Munich, Germany. 4. Department of General, Visceral and Tumor Surgery, University of Cologne, 50937, Köln-Lindenthal, Germany. 5. Department of Internal Medicine III, Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany. stefan.boeck@med.uni-muenchen.de.
Abstract
PURPOSE: Acinar cell carcinoma (ACC) of the pancreas is a very rare cancer, constituting 1 % of all malignant non-endocrine pancreatic tumors. Only very limited data exist to guide treatment in patients with advanced ACC. METHODS: Between 2000 and 2015, 15 patients with ACC were diagnosed and/or treated at our high-volume comprehensive cancer center. Medical records and correlating serum levels of the potential serum tumor markers CA 19-9, CEA and lipase were analyzed retrospectively. RESULTS: A substantial antitumor activity was observed for treatment regimens containing 5-FU and oxaliplatin with partial responses or prolonged disease stabilizations (>12 months) observed in 6 out of 7 patients (86 %). Activity was also observed for single-agent 5-FU and its oral prodrugs. Serum lipase levels were elevated in 7 of 12 patients with advanced disease (58 %), whereas CEA and CA 19-9 seemed to be of minor importance for ACC (elevated pre-treatment levels in 4/12 and 3/12 cases, respectively). In selected patients, repeated serum lipase measurements were available and accurately predicted response to chemotherapy and relapse after surgery. CONCLUSIONS: 5-FU- and oxaliplatin-containing regimens are active in advanced ACC. Lipase kinetics may be a useful novel tool to monitor the course of disease as well as treatment effects in ACC.
PURPOSE:Acinar cell carcinoma (ACC) of the pancreas is a very rare cancer, constituting 1 % of all malignant non-endocrine pancreatic tumors. Only very limited data exist to guide treatment in patients with advanced ACC. METHODS: Between 2000 and 2015, 15 patients with ACC were diagnosed and/or treated at our high-volume comprehensive cancer center. Medical records and correlating serum levels of the potential serum tumor markers CA 19-9, CEA and lipase were analyzed retrospectively. RESULTS: A substantial antitumor activity was observed for treatment regimens containing 5-FU and oxaliplatin with partial responses or prolonged disease stabilizations (>12 months) observed in 6 out of 7 patients (86 %). Activity was also observed for single-agent 5-FU and its oral prodrugs. Serum lipase levels were elevated in 7 of 12 patients with advanced disease (58 %), whereas CEA and CA 19-9 seemed to be of minor importance for ACC (elevated pre-treatment levels in 4/12 and 3/12 cases, respectively). In selected patients, repeated serum lipase measurements were available and accurately predicted response to chemotherapy and relapse after surgery. CONCLUSIONS:5-FU- and oxaliplatin-containing regimens are active in advanced ACC. Lipase kinetics may be a useful novel tool to monitor the course of disease as well as treatment effects in ACC.
Authors: Stephan Kruger; Michael Haas; Steffen Ormanns; Sibylle Bächmann; Jens T Siveke; Thomas Kirchner; Volker Heinemann; Stefan Boeck Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Kyle D Holen; David S Klimstra; Amanda Hummer; Mithat Gonen; Kevin Conlon; Murray Brennan; Leonard B Saltz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Juliann Chmielecki; Katherine E Hutchinson; Garrett M Frampton; Zachary R Chalmers; Adrienne Johnson; Chanjuan Shi; Julia Elvin; Siraj M Ali; Jeffrey S Ross; Olca Basturk; Sohail Balasubramanian; Doron Lipson; Roman Yelensky; William Pao; Vincent A Miller; David S Klimstra; Philip J Stephens Journal: Cancer Discov Date: 2014-09-29 Impact factor: 39.397
Authors: Werner Hartwig; Maike Denneberg; Frank Bergmann; Thilo Hackert; Ulf Hinz; Oliver Strobel; Markus W Büchler; Jens Werner Journal: Am J Surg Date: 2011-03-27 Impact factor: 2.565
Authors: Yuchen Jiao; Raluca Yonescu; G Johan A Offerhaus; David S Klimstra; Anirban Maitra; James R Eshleman; James G Herman; Weijie Poh; Lorraine Pelosof; Christopher L Wolfgang; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos; Laura D Wood Journal: J Pathol Date: 2014-03 Impact factor: 7.996
Authors: Jason C Hall; Laura A Marlow; Adam C Mathias; Louis K Dawson; William F Durham; Kenneth A Meshaw; Robert J Mullin; Aidan J Synnott; Daniel L Small; Murli Krishna; Daniel von Hoff; Julia Schüler; Steven N Hart; Fergus J Couch; Gerardo Colon-Otero; John A Copland Journal: J Transl Med Date: 2016-05-10 Impact factor: 5.531
Authors: Sebastian Zundler; Ramona Erber; Abbas Agaimy; Arndt Hartmann; Franklin Kiesewetter; Deike Strobel; Markus F Neurath; Dane Wildner Journal: BMC Cancer Date: 2016-02-20 Impact factor: 4.430
Authors: Rainer Christoph Miksch; Tobias S Schiergens; Maximilian Weniger; Matthias Ilmer; Philipp M Kazmierczak; Markus O Guba; Martin K Angele; Jens Werner; Jan G D'Haese Journal: World J Clin Cases Date: 2020-11-06 Impact factor: 1.337
Authors: Ekaterina Petrova; Joachim Wellner; Anne K Nording; Rüdiger Braun; Kim C Honselmann; Louisa Bolm; Richard Hummel; Monika Klinkhammer-Schalke; Sylke Ruth Zeissig; Kees Kleihues van Tol; Sylvia Timme-Bronsert; Peter Bronsert; Sergey Zemskov; Tobias Keck; Ulrich Friedrich Wellner Journal: Cancers (Basel) Date: 2021-12-04 Impact factor: 6.639
Authors: Heike Aupperle-Lellbach; Katrin Törner; Marlies Staudacher; Christina Stadler; Ursula Tress; Julia M Grassinger; Elisabeth Müller; Corinna N Weber Journal: J Vet Intern Med Date: 2020-05-07 Impact factor: 3.333
Authors: Elena Busch; Simon Kreutzfeldt; Abbas Agaimy; Gunhild Mechtersheimer; Peter Horak; Benedikt Brors; Barbara Hutter; Martina Fröhlich; Sebastian Uhrig; Philipp Mayer; Evelin Schröck; Albrecht Stenzinger; Hanno Glimm; Dirk Jäger; Christoph Springfeld; Stefan Fröhling; Stefanie Zschäbitz Journal: Cold Spring Harb Mol Case Stud Date: 2020-08-25